# Systemic Inflammatory Response to Cardiopulmonary Bypass

## Introduction

Cardiopulmonary bypass initiates a systemic inflammatory response syndrome (SIRS) that affects virtually every organ system. Blood contact with artificial circuit surfaces, ischemia-reperfusion injury, endotoxemia, and surgical trauma activate complement, coagulation, and cytokine cascades. While most patients tolerate this inflammatory insult, a subset develops clinically significant organ dysfunction including vasoplegia, pulmonary injury, renal failure, and neurocognitive decline.

## Pathophysiology

### Contact Activation

Blood exposure to non-endothelialized circuit surfaces activates the contact pathway (factor XII, kallikrein, high-molecular-weight kininogen), generating bradykinin, a potent vasodilator and mediator of increased vascular permeability. Complement activation via the alternative pathway produces the anaphylatoxins C3a and C5a.

### Complement Activation

C3a and C5a recruit and activate neutrophils, promote endothelial adhesion, and stimulate mast cell degranulation. C5a is the most potent inflammatory mediator, driving neutrophil chemotaxis, reactive oxygen species generation, and tissue injury. Complement activation peaks within minutes of CPB initiation.

### Cytokine Release

Pro-inflammatory cytokines including TNF-alpha, IL-1beta, IL-6, and IL-8 are released from activated monocytes and endothelial cells. Anti-inflammatory cytokines (IL-10, IL-1 receptor antagonist) are simultaneously released as a counter-regulatory response. The balance between pro- and anti-inflammatory mediators determines the clinical severity of SIRS.

### Endothelial Activation and Neutrophil Sequestration

Endothelial cells upregulate adhesion molecules (E-selectin, ICAM-1, VCAM-1), and activated neutrophils marginate in pulmonary, renal, and cerebral microvasculature. Neutrophil degranulation releases elastase, myeloperoxidase, and reactive oxygen species, causing direct tissue injury. Endothelial glycocalyx degradation increases capillary permeability and edema formation.

### Endotoxemia

Gut mucosal hypoperfusion during CPB allows bacterial translocation and endotoxin entry into the circulation. Endotoxin activates toll-like receptor 4 (TLR4) on monocytes, amplifying cytokine production. This process is more pronounced with prolonged CPB and non-pulsatile flow.

![Diagram of the inflammatory cascade triggered by cardiopulmonary bypass showing complement, cytokine, and neutrophil activation](/images/cpb-inflammatory-cascade.png)

## Clinical Manifestations

### Vasoplegia

Vasoplegia presents as distributive shock with low systemic vascular resistance despite adequate cardiac output, mediated by excessive nitric oxide production, bradykinin, and inflammatory vasodilation. It occurs in 5-25% of cardiac surgery patients, with risk factors including preoperative ACE inhibitor/ARB use, prolonged CPB, and preoperative heart failure. Management may require high-dose vasopressors including norepinephrine and vasopressin.

### Pulmonary Dysfunction

Neutrophil sequestration in pulmonary capillaries causes endothelial damage and alveolar edema, manifested as impaired gas exchange, increased A-a gradient, and reduced compliance. Severity ranges from mild atelectasis to severe ARDS in 1-2% of cases.

### Acute Kidney Injury

AKI occurs in 20-30% of cardiac surgery patients, with 2-5% requiring dialysis. The etiology is multifactorial, involving inflammatory injury, hemodilution, hypoperfusion, and nephrotoxin exposure. AKI is associated with significantly increased mortality.

### Neurocognitive Dysfunction

Microemboli (gaseous and particulate), inflammation, and cerebral hypoperfusion contribute to neurological complications. Stroke occurs in 1-3% of cases, and neurocognitive decline affects up to 50% at discharge (though most cases resolve). Cerebral inflammatory injury from activated complement and neutrophil infiltration plays a significant role.

### Coagulopathy

Inflammatory activation of coagulation through the tissue factor pathway and fibrinolysis creates an overlap between inflammatory and coagulation cascades, with thrombin generation, platelet activation, and consumption occurring in parallel.

## Strategies to Mitigate the Inflammatory Response

### Circuit Modifications

Biocompatible circuit coatings such as heparin-bonded (Carmeda), phosphorylcholine, or polymer-coated circuits reduce complement and leukocyte activation. Miniaturized circuits decrease priming volume, reducing hemodilution and blood-surface contact area. Closed venous reservoirs eliminate the blood-air interface, reducing protein denaturation. Centrifugal pumps produce less shear-related hemolysis and platelet activation compared to roller pumps.

### Pharmacologic Strategies

Corticosteroids such as methylprednisolone (10-30 mg/kg) administered before CPB inhibit NF-kB and reduce cytokine production; the DECS trial showed reduced infections but the SIRS trial showed no mortality benefit. Tranexamic acid has anti-inflammatory properties beyond its antifibrinolytic effects. Preoperative statin therapy provides anti-inflammatory and endothelial-protective effects. Aprotinin, a serine protease inhibitor with potent anti-inflammatory properties, was removed from the market due to safety concerns identified in the BART trial but has been reintroduced in some countries with restricted indications.

### Surgical Strategies

Off-pump coronary bypass (OPCAB) eliminates CPB-related inflammation and produces reduced inflammatory markers, though the clinical benefit for most patients remains uncertain. Minimally invasive approaches reduce surgical trauma and the inflammatory stimulus. Minimizing CPB duration, avoiding unnecessary hypothermia-rewarming cycles, and maintaining pulsatile flow when possible further mitigate the inflammatory response.

### Ultrafiltration

Ultrafiltration removes inflammatory mediators, excess fluid, and low-molecular-weight substances. Modified ultrafiltration (MUF) after CPB is most studied in pediatric surgery and removes cytokines while concentrating blood components. Conventional ultrafiltration during CPB removes fluid but is less effective at cytokine clearance.

![Comparison of biocompatible circuit surface coatings and their effects on inflammatory markers](/images/cpb-biocompatible-circuits.png)

## Vasoplegia Management

| Agent | Dose | Mechanism | Role | Key Notes |
|-------|------|-----------|------|-----------|
| Norepinephrine | 0.05-0.5 mcg/kg/min | Alpha-1 and beta-1 agonist | First-line | Standard vasopressor for vasoplegia |
| Vasopressin | 0.01-0.04 U/min | V1 receptor agonist | First/second-line | Independent of NO pathway; effective in depleted states |
| Methylene blue | 1-2 mg/kg IV | Inhibits guanylate cyclase and iNOS | Rescue therapy | Contraindicated in G6PD deficiency; interferes with pulse oximetry |
| Hydroxocobalamin | 5 g IV | NO scavenger | Emerging rescue | Alternative to methylene blue |
| Angiotensin II | 20-40 ng/kg/min | AT1 receptor agonist | Refractory cases | FDA-approved for distributive shock; limited cardiac surgery data |

Norepinephrine is the first-line vasopressor. Vasopressin at 0.01-0.04 units/min acts via V1 receptors independent of the nitric oxide pathway. Methylene blue at 1-2 mg/kg IV inhibits guanylate cyclase and nitric oxide synthase and serves as a second-line agent for refractory vasoplegia. Hydroxocobalamin scavenges nitric oxide and is emerging as a rescue agent. Angiotensin II is FDA-approved for refractory distributive shock, though cardiac surgery data remain limited.

![Stepwise algorithm for management of post-CPB vasoplegia](/images/cpb-vasoplegia-management.png)

## Key Clinical Pearls

The systemic inflammatory response is universal after CPB, and clinical significance depends on the balance between pro- and anti-inflammatory responses. Vasoplegia refractory to norepinephrine should prompt consideration of vasopressin and methylene blue before escalating to high-dose catecholamines. Biocompatible circuit coatings and miniaturized circuits reduce inflammatory activation and should be standard practice. Preoperative ACE inhibitor and ARB use are modifiable risk factors for vasoplegia, and consideration should be given to holding these medications 24-48 hours before surgery. Off-pump surgery eliminates CPB-related inflammation but does not eliminate all surgical inflammatory stimuli, making patient selection key.

## References

1. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. *Eur J Cardiothorac Surg*. 2002;21(2):232-244.
2. Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;386(10000):1243-1253.
3. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. *Ann Thorac Surg*. 2003;75(2):S715-S720.
4. Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. *Am J Med Sci*. 2015;349(1):80-88.